Rest Of Europe Multiomics Market (2026-2031)
The Rest Of Europe Multiomics Market was valued at $218.7 Million in 2026 and projected to reach to $356.9 Million by 2031, representing a compound annual growth rate of 10.3%. Rest Of Europe's multiomics market demonstrates steady expansion driven by increasing healthcare investments and growing recognition of integrated molecular analysis benefits.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe Multiomics Market Trends and Insights
- This 10.3% compound annual growth rate reflects increasing adoption of integrated genomic, proteomic, and metabolomic technologies across Rest Of Europe's healthcare and research sectors.
- Rest Of Europe is positioning itself as a key hub for precision medicine innovation, driven by rising investments in life sciences infrastructure and regulatory support for advanced diagnostic platforms. The multiomics landscape in Rest Of Europe is characterized by growing demand from academic institutions, clinical laboratories, and pharmaceutical companies seeking comprehensive molecular profiling capabilities.
- Rest Of Europe's healthcare systems are increasingly integrating multiomics data into personalized treatment protocols, particularly in oncology and rare disease diagnostics.
- Between 2026 and 2031, Rest Of Europe is expected to see accelerated adoption of multiomics solutions as healthcare providers recognize the clinical and economic value of simultaneous analysis across multiple biological layers..
Key Market Statistics
- CAGR (2026-2031) 10.3% CAGR
- Market Size, 2026 ~USD 218.7 Million
- Forecast, 2031 ~USD 356.9 Million
- Country Rest Of Europe
Rest Of Europe Multiomics Market Overview
Market Valuation Growth :
Rest Of Europe's multiomics market is valued at $218.7 million in 2026, with projections reaching $356.9 million by 2031, representing a robust 10.3% CAGR over the forecast period.
Regional Technology Adoption :
Rest Of Europe is experiencing increasing adoption of integrated genomic, proteomic, and metabolomic technologies across healthcare institutions and research centers, driving market expansion.
Precision Medicine Hub :
The region is positioning itself as a key hub for precision medicine initiatives, leveraging multiomics platforms to enhance diagnostic accuracy and personalized treatment strategies.
Healthcare Sector Integration :
Growing integration of multiomics solutions within Rest Of Europe's healthcare and research sectors reflects commitment to advanced molecular profiling and data-driven clinical decision-making.
Rest Of Europe Multiomics Market Dynamics
- The region's research institutions and clinical laboratories are progressively adopting multiomics platforms to enhance diagnostic capabilities and support precision medicine initiatives.
- Regulatory support and collaborative research networks across Rest Of Europe are facilitating technology adoption and market penetration. The 10.3% CAGR reflects sustained demand for comprehensive genomic, proteomic, and metabolomic solutions in clinical and research settings.
- Rest Of Europe's positioning as a precision medicine hub, combined with advancing healthcare infrastructure and rising healthcare expenditures, is expected to drive continued market growth through 2031.
- Strategic partnerships and innovation in multiomics technologies will further accelerate regional market development..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Rest Of Europe's multiomics market will grow from $218.7M (2026) to $356.9M (2031), representing a 10.3% CAGR.
- Rest Of Europe is experiencing increased adoption of integrated genomic, proteomic, and metabolomic technologies in clinical and research settings.
- Rest Of Europe's healthcare systems are prioritizing personalized medicine approaches, particularly in oncology and rare disease diagnostics.
- Rest Of Europe's market growth is driven by rising life sciences investments, regulatory support, and demand from academic and clinical institutions.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
Rest Of Europe Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- Multiomics Solution Providers : Companies developing genomic, proteomic, and metabolomic platforms need Rest Of Europe-specific market data to assess regional demand, identify clinical adoption opportunities, and develop localized go-to-market strategies.
- Healthcare Investment Firms : Private equity and venture capital investors require detailed Rest Of Europe market analysis to evaluate investment opportunities in precision medicine and multiomics technologies with clear growth trajectories.
- Clinical Laboratory Networks : Hospital systems and diagnostic laboratories across Rest Of Europe need market intelligence to justify multiomics platform investments, benchmark against regional competitors, and plan service expansion.
- Research Institution Leaders : Academic medical centers and research organizations require Rest Of Europe market data to secure funding, demonstrate technology relevance, and establish collaborative research initiatives in precision medicine.
- Healthcare Consultants & Strategists : Management consulting firms advising healthcare clients need Rest Of Europe-specific multiomics market insights to develop regional strategies, identify growth opportunities, and support client decision-making.
Reasons to Buy this Report
- Regional Market Sizing : Obtain precise market valuation data specific to Rest Of Europe, including 2026 baseline ($218.7M) and 2031 projections ($356.9M), enabling accurate regional business planning and investment decisions.
- Growth Trajectory Analysis : Understand Rest Of Europe's 10.3% CAGR within the context of global 12.3% growth, identifying regional market dynamics and competitive positioning opportunities for multiomics solutions.
- Technology Adoption Insights : Access detailed intelligence on integrated genomic, proteomic, and metabolomic technology adoption patterns across Rest Of Europe's healthcare and research sectors for targeted market entry strategies.
- Precision Medicine Positioning : Leverage insights into Rest Of Europe's emerging role as a precision medicine hub to identify partnership opportunities, clinical integration pathways, and regulatory requirements for multiomics platforms.
- Competitive Landscape Intelligence : Gain comprehensive understanding of Rest Of Europe's market structure, key players, and growth drivers to inform product development, pricing strategies, and market expansion initiatives.
Frequently asked questions
What is the current size of Rest Of Europe's multiomics market?
Rest Of Europe's multiomics market is valued at $218.7 million in 2026 and is expected to reach $356.9 million by 2031.
What is the projected growth rate for Rest Of Europe's multiomics market?
Rest Of Europe's multiomics market is projected to grow at a compound annual growth rate (CAGR) of 10.3% from 2026 to 2031.
Which sectors are driving multiomics adoption in Rest Of Europe?
Rest Of Europe's multiomics adoption is driven by academic institutions, clinical laboratories, pharmaceutical companies, and healthcare providers implementing precision medicine protocols.
What applications are most prominent in Rest Of Europe's multiomics market?
Rest Of Europe's multiomics market is seeing strong adoption in oncology diagnostics, rare disease identification, and personalized treatment planning.
What factors are supporting Rest Of Europe's multiomics market growth?
Rest Of Europe's market growth is supported by increased life sciences investments, favorable regulatory frameworks, rising demand for precision medicine, and technological advancements in data integration.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- Canada Multiomics Market
- US Multiomics Market
- Germany Multiomics Market
- UK Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- China Multiomics Market
- Japan Multiomics Market
- South Korea Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
